Ono Pharmaceutical said on March 28 that it has concluded a research and option agreement with Swiss biotech Numab Therapeutics for the discovery and development of a multi-specific antibody candidate in the immuno-oncology space. Under the deal, Ono will have…
To read the full story
Related Article
- Ono Strikes New Oncology Pact with Numab
February 15, 2024
- Ono Bags Global Rights to Numab’s Multispecific I/O Antibody
April 1, 2022
- Ono Expands I/O Collaboration with Swiss Firm Numab
March 31, 2020
BUSINESS
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- Towa Seeks Policy Reset on Off-Patent Meds, Says Generic Push Has Run Its Course
July 9, 2026
- Ipsen Rolls Out Japan’s First FOP Treatment Sohonos
July 9, 2026
- Fujifilm Picked for FDA Pilot to Accelerate US CDMO Expansion
July 9, 2026
- Nichi-Iko Exits Turnaround Mode, Eyes Next Growth Phase
July 9, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





